Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

International journal of molecular sciences - 22 Jun 2023

Kekeeva Tatiana, Andreeva Yulia, Tanas Alexander, Kalinkin Alexey, Khokhlova Svetlana, Tikhomirova Tatiana, Tyulyandina Alexandra, Popov Anatoly, Kuzmenko Maria, Volkonsky Mikhail, Chernorubashkina Natalia, Saevets Valeria, Dmitriev Vadim, Nechushkina Valentina, Vedrova Olga, Andreev Sergei, Kutsev Sergey, Strelnikov Vladimir

Abstract excerpt

Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice. The HRD status, including the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Homologous Recombination

Share to Mutation

Share to Ovarian Neoplasms

Share to Russia

Source

Open in PubMed Open full text

Identifiers

PMID: 37445679
DOI: 10.3390/ijms241310497
PMCID: PMC10342032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?PMID 37445679Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical ConsiderationsSemantic proximity Read ↗

Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.Semantic proximity Read ↗

Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment.Semantic proximity Read ↗

In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot studySemantic proximity Read ↗

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnosticsSemantic proximity Read ↗

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)Semantic proximity Read ↗

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?Semantic proximity Read ↗

HRD-One: CLINICAL VALIDATION AND PERFORMANCE ASSESSMENT. Comparison between Myriad’s myChoice®, SOPHiA GENETICS® SOPHiA Homologous Recombination Solution and AmoyDx® HRD Focus PanelSemantic proximity Read ↗

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer DiagnosisSemantic proximity Read ↗

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialSemantic proximity Read ↗

Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World CohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.